Skip to main content
Clinical Trials/NCT05786664
NCT05786664
Recruiting
Not Applicable

A Comprehensive Breast Cancer Survivorship Biorepository

University of Southern California1 site in 1 country1,300 target enrollmentApril 11, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Anatomic Stage I Breast Cancer AJCC v8
Sponsor
University of Southern California
Enrollment
1300
Locations
1
Primary Endpoint
Biorepository
Status
Recruiting
Last Updated
4 months ago

Overview

Brief Summary

This study collects blood samples as well as clinical and self-report data from stage I-III breast cancer survivors to create a biorepository for future use. The creation of this biorepository will allow for future research into links between individual, molecular, and genomic signatures and cancer outcomes.

Detailed Description

PRIMARY OBJECTIVE: I. To create an annotated biorepository with prospectively collected blood samples from breast cancer survivors. SECONDARY OBJECTIVES: I. To collect comprehensive data on social determinants of health (e.g., race/ethnicity, acculturation, socioeconomic status, and access to care), environmental exposures (based on zip codes/geocoding), lifestyle (e.g., diet, tobacco use), clinicopathologic characteristics, treatment history, follow-up and current disease status, survivorship-related issues. II. To establish an efficient process for researchers to utilize the biorepository for breast cancer and survivorship-related studies. OUTLINE: Patients complete surveys, undergo collection of blood samples, and review of medical records on study.

Registry
clinicaltrials.gov
Start Date
April 11, 2022
End Date
April 11, 2028
Last Updated
4 months ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Women of all racial and ethnic groups 18 years of age or older
  • Women with a diagnosis of invasive breast cancer (stages I-III) within the past 7 years
  • Women who have completed active treatment for breast cancer (surgery, chemotherapy, HER2-directed therapy and radiation)
  • Prior participation on clinical trials is allowed

Exclusion Criteria

  • Current receipt of interventional clinical trial participation
  • Stage IV (metastatic) cancer
  • Prior history of recurrence (except recurrence following ductal carcinoma in situ)
  • Inability to give informed consent
  • Unable to speak English, Spanish, Chinese, or Korean

Outcomes

Primary Outcomes

Biorepository

Time Frame: 5 years

Number of biological samples collected and stored (blood)

Study Sites (1)

Loading locations...

Similar Trials